NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.24 +0.01 (+4.35 %) (As of 05/20/2018 04:00 PM ET)Previous Close$0.24Today's Range$0.2250 - $0.245052-Week Range$0.21 - $0.68Volume241,034 shsAverage Volume302,216 shsMarket Capitalization$62.36 millionP/E RatioN/ADividend YieldN/ABeta-0.78 Company Profile Financials Earnings History Insider Trades Headlines SEC Filings Social Media Chart About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)TweetNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio. Receive NAVB News and Ratings via Email Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Industry Biotechnology Sub-IndustryHealth Care Equipment SectorMedical SymbolNYSEAMERICAN:NAVB CUSIP63937X10 Webwww.navidea.com Phone+1-614-7937500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-688.85% Return on Equity-38.60% Return on Assets-25.48% Miscellaneous EmployeesN/A Outstanding Shares162,960,000 Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions What is Navidea Biopharmaceuticals' stock symbol? Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB." How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.28 million for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. View Navidea Biopharmaceuticals' Earnings History. Are investors shorting Navidea Biopharmaceuticals? Navidea Biopharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,192,104 shares, an increase of 1.5% from the April 13th total of 4,131,039 shares. Based on an average daily trading volume, of 360,457 shares, the short-interest ratio is presently 11.6 days. Approximately 2.7% of the company's shares are sold short. Who are some of Navidea Biopharmaceuticals' key competitors? Some companies that are related to Navidea Biopharmaceuticals include Bionomics (BNO), Adherex Technologies (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford BioDynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL) and Tiziana Life Sciences (TILS). Who are Navidea Biopharmaceuticals' key executives? Navidea Biopharmaceuticals' management team includes the folowing people: Dr. Michael M. Goldberg, CEO, Pres & Director (Age 59)Mr. Jed A. Latkin, CFO, COO, Sec., Treasurer & Principal Accounting officer (Age 44)Dr. Frederick O. Cope Ph.D., F.A.C.N., C.N.S., Chief Scientific Officer & Sr. VP (Age 71)Mr. William J. Regan, Chief Compliance Officer and Sr. VP of Global Regulatory Affairs & Quality (Age 66)Ms. Sharon Correia, Sr. Director of Corp. Communications Has Navidea Biopharmaceuticals been receiving favorable news coverage? Media coverage about NAVB stock has been trending somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Navidea Biopharmaceuticals' stock price today? One share of NAVB stock can currently be purchased for approximately $0.24. How big of a company is Navidea Biopharmaceuticals? Navidea Biopharmaceuticals has a market capitalization of $62.36 million. How can I contact Navidea Biopharmaceuticals? Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500. MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 121 (Vote Outperform)Underperform Votes: 107 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days. Analyst Ratings Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Analyst Ratings History DateBrokerageActionRatingPrice TargetDetails(Data available from 5/20/2016 forward) Earnings Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings History and Estimates ChartNavidea Biopharmaceuticals (NYSEAMERICAN NAVB) Earnings History by QuarterDateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails5/8/2018Q1 2018($0.04)$0.28 millionViewN/A3/8/2018Q4 2017($0.03)$0.40 millionViewN/A11/7/2017Q3 2017($0.01)$0.22 millionViewN/A8/8/2017Q2 2017($0.02)$0.61 millionViewListen5/9/2017Q1 2017($0.01)$0.58 millionViewN/A3/29/2017Q4 2016($0.02)$3.36 millionViewN/A8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/A5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListen3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListen11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListen7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListen5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListen3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/A3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/A3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListen11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListen8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListen5/7/2014Q114($0.10)($0.06)$0.90 million$0.7520 millionViewListen3/6/2014Q413($0.08)($0.10)$0.74 million$0.5350 millionViewListen11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListen8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/A5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/A3/6/2013Q4 2012($0.08)($0.08)ViewN/A11/8/2012Q312$0.21($0.09)ViewN/A8/6/2012Q2 2012($0.06)($0.06)ViewN/A5/2/2012Q1 2012($0.07)($0.07)ViewN/A2/29/2012Q4 2011($0.05)($0.08)ViewN/A10/26/2011Q3 2011($0.03)($0.07)ViewN/A7/27/2011Q2 2011($0.02)($0.02)ViewN/A5/9/2011Q1 2011($0.02)($0.05)ViewN/A3/7/2011Q4 2010($0.03)($0.03)ViewN/A11/10/2010Q3 2010($0.01)($0.03)ViewN/A8/9/2010Q2 2010($0.02)($0.02)ViewN/A4/28/2010Q1 2010($0.01)($0.03)ViewN/A11/2/2009Q3 2009($0.31)($0.10)ViewN/A8/11/2009Q2 2009($0.02)($0.02)ViewN/A5/6/2009Q1 2009$0.01ViewN/A3/10/2009Q4 2008($0.03)($0.02)ViewN/A11/5/2008Q3 2008($0.02)($0.03)ViewN/A8/4/2008Q2 2008($0.03)($0.02)ViewN/A5/1/2008Q1 2008($0.01)($0.02)ViewN/A3/19/2008Q4 2007($0.01)($0.02)ViewN/A(Earnings results data provided by Zacks Investment Research) Dividends Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Dividend History by QuarterAnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date(Data available from 1/1/2013 forward) Insider Trades Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading and Institutional Ownership HistoryNavidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading HistoryTransaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails6/29/2017William J ReganSVPBuy20,000$0.53$10,600.00172,977 5/30/2017Jed LatkinCFOBuy7,600$0.44$3,344.0050,159 5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.5531,359 12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00222,237 10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00247,237 9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00259,737 6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00 5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00 11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00 11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00 5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00292,674 3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00319,184 3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.0075,814 3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00282,674 11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00139,250 11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00287,304 11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.0090,814 11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00402,674 3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00 3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00 3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00 3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00 9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00 9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00 9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00 (Data available from 1/1/2013 forward) Headlines Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineEdited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMTfinance.yahoo.com - May 10 at 10:06 AMNavidea Biopharmaceuticals, Inc. (NAVB) Sees Large Increase in Short Interestwww.americanbankingnews.com - May 9 at 5:24 PMNavidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - Earnings Call Transcriptseekingalpha.com - May 9 at 4:10 PMNavidea Biopharmaceuticals Reports First Quarter 2018 Financial Resultsfinance.yahoo.com - May 9 at 9:54 AMNavidea: 1Q Earnings Snapshotfinance.yahoo.com - May 9 at 9:54 AMNavidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmithfinance.yahoo.com - May 8 at 9:49 AMNavidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Updatefinance.yahoo.com - May 2 at 4:07 PMNavidea Biopharmaceuticals, Inc. (NAVB) Short Interest Down 0.1% in Aprilwww.americanbankingnews.com - April 26 at 1:14 AMNavidea Biopharmaceuticals to Present at 2nd Annual NASH Summitfinance.yahoo.com - April 24 at 9:55 AMNavidea signs deal to sublicense NAV4694 worldwide development rightsseekingalpha.com - April 16 at 9:56 AMNavidea Biopharmaceuticals, Inc. (NAVB) Short Interest Updatewww.americanbankingnews.com - April 11 at 2:04 AMNavidea Biopharmaceuticals (NAVB) Rating Increased to Hold at ValuEnginewww.americanbankingnews.com - April 9 at 4:05 PMActive-Investors: Wired News - EMA to Review Regeneron's Marketing Authorization Application for Cemiplimabwww.finanznachrichten.de - April 5 at 8:38 AMNavidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trialfinance.yahoo.com - April 3 at 4:13 PMNavidea Biopharmaceuticals Inc (NAVB) Sees Large Decrease in Short Interestwww.americanbankingnews.com - March 27 at 1:54 AMEdited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMTfinance.yahoo.com - March 23 at 9:36 AMNavidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech Industryfinance.yahoo.com - March 23 at 9:36 AMAnnual Future Leaders in the Biotech Industry - Business Wire (press release)www.businesswire.com - March 16 at 10:57 AMNavidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)www.businesswire.com - March 10 at 4:14 PMShort Interest in Navidea Biopharmaceuticals Inc (NAVB) Expands By 0.2%www.americanbankingnews.com - March 10 at 2:52 AMNavidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Resultsfinance.yahoo.com - March 9 at 11:54 AMNavidea Biopharmaceuticals Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Updatefinance.yahoo.com - March 1 at 10:02 AMNavidea Biopharmaceuticals Inc (NAVB) Short Interest Updatewww.americanbankingnews.com - February 9 at 8:28 PMNavidea to Host Moderated Q&A Webcast with Management - Business Wire (press release)www.businesswire.com - February 2 at 5:57 AMNavidea to Host Moderated Q&A Webcast with Managementfinance.yahoo.com - February 2 at 5:57 AMNavidea Biopharmaceuticals Inc (NAVB) Short Interest Down 2.1% in Januarywww.americanbankingnews.com - January 25 at 1:33 AMShort Interest in Navidea Biopharmaceuticals Inc (NAVB) Decreases By 12.0%www.americanbankingnews.com - January 11 at 1:22 AMNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018finance.yahoo.com - January 1 at 9:28 AMNavidea Biopharmaceuticals Inc (NAVB) Sees Significant Increase in Short Interestwww.americanbankingnews.com - December 27 at 6:38 PMNavidea Biopharmaceuticals to Present at Biotech Showcase 2018finance.yahoo.com - December 19 at 5:18 PMNavidea Biopharmaceuticals Inc (NAVB) Short Interest Up 3.6% in Novemberwww.americanbankingnews.com - November 27 at 8:24 PMNavidea Biopharmaceuticals to Present at LD Micro 10 - Business Wire (press release)www.businesswire.com - November 21 at 8:31 AMNavidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Eventfinance.yahoo.com - November 21 at 8:31 AMNavidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Eventfinance.yahoo.com - November 21 at 8:31 AM SEC Filings Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) SEC Filings Form Type: All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Ownership Filings: Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings This page is loading this company's SEC Filings. Please wait... Social Media Financials Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Income Statement, Balance Sheet and Cash Flow Statement Chart Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Stock Chart for Sunday, May, 20, 2018Loading chart… This page was last updated on 5/20/2018 by MarketBeat.com Staff
